FindMyKOL

Amy Warriner

Basic profile

University of Alabama at Birmingham

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionBirmingham, AL · SoutheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLFindMyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Amy Warriner is an Endocrinology/Metabolic physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 51 publications with 1,409 citations (h-index 19); ClinicalTrials.gov lists 2 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
51publications

Publications indexed by OpenAlex. Counts exclude supporting files.

1,409citations

Citations across these publications.

19h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials ↓
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • AbbVie
    Program year20256 paymentsResearch
    $23,772
  • Takeda
    Program year20252 paymentsResearch
    $530
  • Neurocrine BioSciences, Inc.
    Program year20251 payment
    $24
All 14 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    47.6%
    GLP-1 receptor agonist21.3%
    Mounjaro41%Trulicity39%Ozempic20%
    Part D≥28 patients
    Insulin Analog9.6%
    Tresiba Flextouch U-10031%Lantus Solostar25%Novolog Flexpen22%Toujeo Solostar13%Humalog Kwikpen U-1008%
    Part D<11 patients

    + 4 more classes in this area

  • Hormonal (systemic)

    24.6%
    Parathyroid Hormone Analog10.5%
    Forteo100%
    Part D≥30 patients
    l-Thyroxine10.1%
    Levothyroxine Sodium87%Synthroid13%
    Part D<11 patients

    + 2 more classes in this area

  • Musculoskeletal

    13%
    Bisphosphonate5.4%
    Zoledronic Acid100%
    Part D≥101 patients
    Bisphosphonates3.8%
    Risedronate Sodium100%
    Part D≥17 patients

    + 3 more classes in this area

Where care is delivered (Part B)82.9% facility · 17.1% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”